FIDELIS ANIMAL HEALTH, INC. – Trademark Portfolio
Entity Type: 03
FIDELIS ANIMAL HEALTH, INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ETHIQA XR, FIDELIS PHARMACEUTICALS, and ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML. The owner is based in NORTH BRUNSWICK, NJ.
675 HIGHWAY ONE
, SUITE B113
NORTH BRUNSWICK, NJ 08902
Showing of trademarks Trademarks
Trademark Classifications
FIDELIS ANIMAL HEALTH, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does FIDELIS ANIMAL HEALTH, INC. have?
FIDELIS ANIMAL HEALTH, INC. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does FIDELIS ANIMAL HEALTH, INC. file in?
FIDELIS ANIMAL HEALTH, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are FIDELIS ANIMAL HEALTH, INC.'s most well-known trademarks?
FIDELIS ANIMAL HEALTH, INC.'s registered trademark portfolio includes well-known marks such as ETHIQA XR, FIDELIS PHARMACEUTICALS, and ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML. These are among 3 currently registered trademarks in the portfolio.
What is FIDELIS ANIMAL HEALTH, INC.'s trademark registration success rate?
FIDELIS ANIMAL HEALTH, INC. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.